TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22386229

Group type: EXPERIMENTAL
Intervention: Quantitative enzyme-linked immunoassay (EIA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rocket immune-electrophoresis (RIE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chromatographic immunoassay (CIA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-reported condom failures
Number of subjects: 30
Study: 20441129

Group type: EXPERIMENTAL
Intervention: Experimental focus that fits chronic self-regulatory focus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfit conditions
Number of subjects: 0
Study: 17592653

Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Mailed questionnaires
Number of subjects: 4000
Study: 16350679

Group type: EXPERIMENTAL
Intervention: Combined supplementation of fish oil (600 mg) with garlic pearls (500 mg) per day for 60 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 16
Study: 12486987

Group type: EXPERIMENTAL
Intervention: Computer and paper reporting methods
Number of subjects: 42
Study: 9794052

Group type: EXPERIMENTAL
Intervention: Functional restoration program for patients with moderate low back pain.
Number of subjects: 160

Group type: COMPARATOR
Intervention: One-footed postural control measurement.
Number of subjects: 160

Group type: COMPARATOR
Intervention: One-footed postural stability measurement.
Number of subjects: 160
Study: 7667128

Group type: EXPERIMENTAL
Intervention: Disposable thermometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mercury thermometer
Number of subjects: 0
Study: 2570701

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: cetirizine diHCl 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 1183219

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fluocinolone acetonide ointment
Number of subjects: 29
Study: 31271308

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no additional plyometric training)
Number of subjects: 18
Study: 28957407

Group type: EXPERIMENTAL
Intervention: Semiconductor laser irradiation at 1W for 20 seconds
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasonic rinsing for 60 seconds
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment prior to RCT)
Number of subjects: 60
Study: 25986641

Group type: EXPERIMENTAL
Intervention: Health consultation involving a self-help manual, monthly prompts, and spirometry
Number of subjects: 550

Group type: COMPARATOR
Intervention: Spirometry followed by usual care (Control)
Number of subjects: 550
Study: 23892341

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 250 mg (steroid group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard PVI without IV hydrocortisone (nonsteroid group)
Number of subjects: 90
Study: 21894706

Group type: EXPERIMENTAL
Intervention: Acupotomology
Number of subjects: 184

Group type: COMPARATOR
Intervention: Operation
Number of subjects: 184
Study: 19254601

Group type: EXPERIMENTAL
Intervention: Land-based exercise program
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pool-based exercise program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 82
Study: 17197377

Group type: EXPERIMENTAL
Intervention: Immediate substitution with lopinavir/ritonavir 400/100 mg bid
Number of subjects: 849
Study: 10232529

Group type: EXPERIMENTAL
Intervention: Ultraearly angiographic vasospasm (UEAV)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Early surgery (within 48 h of hemorrhage onset)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Patients with UEAV who did not undergo early surgery
Number of subjects: 296
Study: 8916803

Group type: EXPERIMENTAL
Intervention: Artemisinin + Quinine (AQ)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Artemisinin + Doxycycline (AD)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Quinine (Q)
Number of subjects: 161
Study: 1926985

Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg bid)
Number of subjects: 11
Study: 6126170

Group type: EXPERIMENTAL
Intervention: THIP (10 to 25 mg single dose; 20 to 120 mg daily for four weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30890001

Group type: EXPERIMENTAL
Intervention: Withholding enteral feeding (NPO) during RBC transfusion
Number of subjects: 112

Group type: COMPARATOR
Intervention: Continuance of feeding (FED) during RBC transfusion
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: NPO and FED groups
Number of subjects: 112
Study: 31515185

Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy (DHC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study: 29341471

Group type: EXPERIMENTAL
Intervention: Maximal tolerated dose of valsartan (titrated up to 320 mg/day, n=333)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Low-dose valsartan (80 mg/day, n=162)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Maximal tolerated dose of valsartan (titrated up to 320 mg/day)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Low-dose valsartan (80 mg/day)
Number of subjects: 495
Study: 25952055

Group type: EXPERIMENTAL
Intervention: Home-based self-management rehabilitation programme
Number of subjects: 128
Study: 23760035

Group type: EXPERIMENTAL
Intervention: Bifrontal and bitemporal electrode placements during ECT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Seizure duration during ECT
Number of subjects: 40
Study: 22174029

Group type: EXPERIMENTAL
Intervention: Atomoxetine (Atx) 80 mg daily for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Atomoxetine (Atx)
Number of subjects: 64
Study: 21143048

Group type: EXPERIMENTAL
Intervention: Australian Medical Sheepskin
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1281
Study: 17697477

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 71
Study: 15616046

Group type: EXPERIMENTAL
Intervention: J-tip directed caudad (Group 1)
Number of subjects: 295

Group type: COMPARATOR
Intervention: J-tip directed cephalad (Group 2)
Number of subjects: 295
Study: 12472369

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 0
Study: 10084468

Group type: EXPERIMENTAL
Intervention: Ipratropium plus Albuterol
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Ipratropium plus Albuterol and Ipratropium
Number of subjects: 1067
Study: 7604808

Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption (70 g of ethanol diluted to 20% with lemonade)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference (lemonade alone)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference
Number of subjects: 10
Study: 2195934

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg three times per day for 14 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30704412

Group type: EXPERIMENTAL
Intervention: Heavy load resistance training (HRT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate load resistance training (MRT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study: 29136270

Group type: EXPERIMENTAL
Intervention: 60 Seconds to Survival (60S) video game; played at least three times over 13 weeks.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no disaster training during the study).
Number of subjects: 47
Study: 26802969

Group type: EXPERIMENTAL
Intervention: Electromechanical gait trainer (GT) combined with conventional physiotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional physiotherapy alone
Number of subjects: 106
Study: 24422622

Group type: EXPERIMENTAL
Intervention: High level model of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low level model of care
Number of subjects: 0
Study: 22766970

Group type: EXPERIMENTAL
Intervention: Fractional CO(2) laser treatments (3 monthly sessions, MedArt 610; 12-14 W, 48-56 mJ/pulse, 13% density)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 13
Study: 20362975

Group type: EXPERIMENTAL
Intervention: ERP+DCS
Number of subjects: 22

Group type: COMPARATOR
Intervention: ERP+placebo
Number of subjects: 22
Study: 17110643

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 15507534

Group type: EXPERIMENTAL
Intervention: [3H]triolein
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: [14C]triolein
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Menstrual cycle factors
Number of subjects: 24
Study: 12016098

Group type: EXPERIMENTAL
Intervention: Theophylline (plasma level of 9-11 mg/L) for 4 weeks
Number of subjects: 25
Study: 10198737

Group type: EXPERIMENTAL
Intervention: NC100100
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Intermittent harmonic imaging with NC100100 at 0.03 microliter particles/kg body weight
Number of subjects: 203
Study: 8778133

Group type: EXPERIMENTAL
Intervention: Clear description profiles
Number of subjects: 5

Group type: COMPARATOR
Intervention: Unclear description profiles
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Neurotic simulation profiles
Number of subjects: 5

Group type: COMPARATOR
Intervention: Psychotic simulation profiles
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Authentic profiles
Number of subjects: 5

Group type: COMPARATOR
Intervention: Simulated profiles
Number of subjects: 5
Study: 2171115

Group type: EXPERIMENTAL
Intervention: Self-adhesive electrodes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ordinary electrodes
Number of subjects: 26
Study: 346628

Group type: EXPERIMENTAL
Intervention: Active treatment (cat pelt extract)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31362784

Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bupropion (300 mg per day)
Number of subjects: 65
Study: 27632069

Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Lactated Ringer solution (LR; placebo)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Narcotic use
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) use
Number of subjects: 98
Study: 26502867

Group type: EXPERIMENTAL
Intervention: Casperome® 500 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 32
Study: 23810644

Group type: EXPERIMENTAL
Intervention: Topiramate, 300 mg daily
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 21543963

Group type: EXPERIMENTAL
Intervention: 16 g total dietary fiber per day from psyllium
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Steady dose segment (all fiber sources)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Total symptom severity and emotional upset
Number of subjects: 189
Study: 18793657

Group type: EXPERIMENTAL
Intervention: Response procedure using drawings (crossing out face drawings)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Response procedure using words (circling corresponding words)
Number of subjects: 67
Study: 17456571

Group type: EXPERIMENTAL
Intervention: Cabergoline (Cb2) 0.5 mg/d
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 15628041

Group type: EXPERIMENTAL
Intervention: Salmeterol (2 x 50 microg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ipratropium bromide (4 x 40 microg/day)
Number of subjects: 24
Study: 11346842

Group type: EXPERIMENTAL
Intervention: Severe TBI group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mild TBI group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (non-TBI trauma)
Number of subjects: 51
Study: 9562228

Group type: EXPERIMENTAL
Intervention: Acesal (rapidly dispersing acetylsalicylic acid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acesal Extra (rapidly dispersing acetylsalicylic acid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Micristin (microencapsuled acetylsalicylic acid)
Number of subjects: 24
Study: 7881507

Group type: COMPARATOR
Intervention: State hospital delivery
Number of subjects: 221

Group type: COMPARATOR
Intervention: Private hospital delivery
Number of subjects: 221

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 221

Group type: COMPARATOR
Intervention: Caesarean delivery
Number of subjects: 221
Study: 3259110

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopentone-isoflurane
Number of subjects: 50
Study: 31586305

Group type: EXPERIMENTAL
Intervention: Back Propagation Neural Network (BPNN) model
Number of subjects: 13639

Group type: COMPARATOR
Intervention: Multiple Linear Regression (MLR) model
Number of subjects: 13639
Study: 29519777

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) for 14 weeks (n=117)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n=122)
Number of subjects: 239
Study: 29061168

Group type: EXPERIMENTAL
Intervention: Silence is Deadly program
Number of subjects: 8

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 8
Study: 26338889

Group type: EXPERIMENTAL
Intervention: Dal (lentils enriched to 85.1% with (57)Fe, 8 mg native (57)Fe)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ferrous sulfate (7 mg FeSO4 plus 1 mg (58)Fe)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dal (for anemic women)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (for anemic women)
Number of subjects: 19
Study: 23081872

Group type: EXPERIMENTAL
Intervention: Digital ovulation tests
Number of subjects: 210
Study: 20846920

Group type: COMPARATOR
Intervention: AR (CAG)(>24)/(CAG)(>24) genotype category
Number of subjects: 1960

Group type: COMPARATOR
Intervention: AR (GGC)(17)/(GGC)(14) genotype
Number of subjects: 1960
Study: 18301184

Group type: EXPERIMENTAL
Intervention: Human Performance Simulator (HPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic Lecture (LEC)
Number of subjects: 0
Study: 17138176

Group type: EXPERIMENTAL
Intervention: Tacrolimus powder in Orabase 0.1%
Number of subjects: 10
Study: 14744167

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 11767269

Group type: EXPERIMENTAL
Intervention: School-based prevention program
Number of subjects: 2041

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2041
Study: 9406836

Group type: EXPERIMENTAL
Intervention: hMG (human menopausal gonadotropin)
Number of subjects: 13

Group type: COMPARATOR
Intervention: recombinant FSH
Number of subjects: 13
Study: 8427539

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 or 1000 mg daily (n = 21)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1500 or 2000 mg daily (n = 56)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Continuous treatment with clarithromycin
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Stopped treatment for 7 days or longer
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Concomitant AIDS drugs
Number of subjects: 77
Study: 3304027

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30290775

Group type: EXPERIMENTAL
Intervention: Paclitaxel chemotherapy
Number of subjects: 57
Study: 27055722

Group type: EXPERIMENTAL
Intervention: Written briefing
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Telephone briefing
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Face-to-face information
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Control group (no briefing)
Number of subjects: 1690
Study: 24299021

Group type: EXPERIMENTAL
Intervention: Montelukast treatment for 3 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 130
Study: 22406028

Group type: EXPERIMENTAL
Intervention: WEI JET (Supraglottic jet ventilation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional endotracheal tube (control group)
Number of subjects: 0
Study: 20864606

Group type: EXPERIMENTAL
Intervention: Life skills programme 'Eigenständig werden' (Becoming independent)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 919
Study: 18684077

Group type: EXPERIMENTAL
Intervention: OPC Factor
Number of subjects: 25
Study: 15959851

Group type: EXPERIMENTAL
Intervention: [(11)C]d-threo-methylphenidate ([(11)C]dMP) in PD patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study: 14509153

Group type: EXPERIMENTAL
Intervention: Garlic (alliin 22.4 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10204589

Group type: EXPERIMENTAL
Intervention: Filtered whole blood
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Washed red cells
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no transfusions)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 27
Study: 7590497

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO) at a dose of 40 mg/kg/day as a 24-hour intravenous infusion from day -9 to day +60
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO)
Number of subjects: 15
Study: 2671247

Group type: EXPERIMENTAL
Intervention: Intensified conventional insulin treatment (ICT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Regular treatment (RT)
Number of subjects: 95
Study: 1101904

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide 10 mg t.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flupenthixole 0.5 mg t.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide with alcohol (0.5 g/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flupenthixole with alcohol (0.5 g/kg)
Number of subjects: 20
Study: 30829050

Group type: EXPERIMENTAL
Intervention: OTO-201 (0.2 mL, 12 mg, n = 130)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Sham (air injection, n = 130)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: OTO-201
Number of subjects: 260
Study: 28982378

Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 0
Study: 25041226

Group type: EXPERIMENTAL
Intervention: Resistive exercise with whole-body vibrations (RVE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resistive exercise (RE)
Number of subjects: 26
Study: 24254557

Group type: EXPERIMENTAL
Intervention: 1 cc 1% lidocaine before biopsy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional biopsy without local anesthesia
Number of subjects: 80
Study: 21270143

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 382

Group type: COMPARATOR
Intervention: Oral antipsychotic regimen selected by control patient's psychiatrist
Number of subjects: 382
Study: 19091331

Group type: EXPERIMENTAL
Intervention: 200 microg selenium orally daily (selenium group of 116)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: 600 mg N-acetyl-cysteine orally daily (N-acetyl-cysteine group of 118)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: 200 microg selenium plus 600 mg N-acetyl-cysteine orally daily (selenium plus N-acetyl-cysteine group of 116)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo (control group of 118)
Number of subjects: 468
Study: 17185202

Group type: EXPERIMENTAL
Intervention: Depo Now
Number of subjects: 333

Group type: COMPARATOR
Intervention: Bridge method
Number of subjects: 333
Study: 15546289

Group type: EXPERIMENTAL
Intervention: Cypher stent
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Taxus stent
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Taxus stent (long lesions)
Number of subjects: 1108
Study: 11310696

Group type: EXPERIMENTAL
Intervention: Administration of blood products through central venous catheters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia during catheterization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central venous catheter insertion under maximal sterile barrier precautions
Number of subjects: 0
Study: 9741495

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 142

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 142
Study: 7750678

Group type: EXPERIMENTAL
Intervention: Lactulose-neomycin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 3773728

Group type: EXPERIMENTAL
Intervention: 30 IU/kg heparin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 50 IU/kg heparin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 75 IU/kg heparin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 100 IU/kg heparin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Repeated daily injections of 75 IU/kg heparin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Infusion of heparin or saline on three consecutive days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined subjects over time
Number of subjects: 19